Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00659230 | Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans | PHASE2 | COMPLETED | 100 | — | — | Jul 1, 2009 | Aug 30, 2012 | Oct 13, 2017 | 3 | United States |
The Clinician Administered PTSD Scale subscore D (CAPS-D) measures the hyperarousal cluster for PTSD symptoms (5 items). Higher scores indicate greater severity. Range for CAPS-D is zero to 40. The CAPS has acceptable test-retest reliability (0.98), sensitivity (0.84), specificity (0.95), internal consistency (0.76-0.88) and validity (κ=0.78).
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Arm 1 |
| Nepicastat | ACTIVE_COMPARATOR | Arm 2 |
| Name | Type | Description |
|---|---|---|
| Nepicastat | DRUG | 100-800mg |
| Placebo | DRUG | 100-800mg placebo |
Inclusion Criteria: * Signed informed consent * Patient understands the risks and benefits and agrees to visit frequency and procedures * Male or female * Any race or ethnic origin * Served in OIF/OEF or Afghanistan conflicts or other Southwest Asia conditions * Currently Active Duty, National Guar...